All In Biotech

Drug Trial Radar · NCT05067335

A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis

Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 327 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

327

Actual

Start

Oct 21, 2021

Primary completion

Nov 9, 2023

Study completion Nov 9, 2023

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
Oct 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 55 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the effect of treatment with romosozumab for 6 months compared with placebo on the percent changes in bone mineral density (BMD) at the lumbar spine, at the total hip and femoral neck in postmenopausal Chinese women with osteoporosis.

Conditions

  • Osteoporosis

Interventions

  • RomosozumabDrug

    Subjects will receive romosozumab in a specified sequence during the treatment Period.

  • PlaceboDrug

    Subjects will receive Placebo in a specified sequence during the treatment Period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine to the End of Double-Blind PeriodTime frame: From Baseline (Day 1) to the end of the Double-blind Period (Month 6)
  2. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Double-Blind PeriodTime frame: From Baseline to the end of the Double-blind Period (Month 6)
  3. Percentage of Participants With Treatment-emergent Adverse Events for Romosozumab During Overall PeriodTime frame: From Month 7 up to Month 12 (Placebo/Romo) and From Day 1 up to Month 12 (Romo/Romo) + 3-month SFU (up to Month 15)

Locations

30 sites in 1 country. Site status is shown where the registry gives one.

  • Op0002 20040

    Beijing, China

  • Op0002 20115

    Beijing, China

  • Op0002 20125

    Beijing, China

  • Op0002 20127

    Beijing, China

  • Op0002 20128

    Beijing, China

  • Op0002 20130

    Beijing, China

  • Op0002 20131

    Beijing, China

  • Op0002 20157

    Beijing, China

  • Op0002 20021

    Chengdu, China

  • Op0002 20133

    Chengdu, China

  • Op0002 20137

    Chengdu, China

  • Op0002 20205

    Foshan, China

  • Op0002 20117

    Guangzhou, China

  • Op0002 20124

    Guangzhou, China

  • Op0002 20209

    Nanchang, China

  • Op0002 20135

    Nanjing, China

  • Op0002 20202

    Pingxiang, China

  • Op0002 20199

    Rui’an, China

  • Op0002 20116

    Shanghai, China

  • Op0002 20118

    Shanghai, China

  • Op0002 20121

    Shanghai, China

  • Op0002 20123

    Shanghai, China

  • Op0002 20129

    Shanghai, China

  • Op0002 20119

    Suzhou, China

  • Op0002 20204

    Suzhou, China

  • Op0002 20122

    Tianjin, China

  • Op0002 20136

    Tianjin, China

  • Op0002 20120

    Wuhan, China

  • Op0002 20134

    Yueyang, China

  • Op0002 20132

    Zhengzhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.